Estrogen (ER), progesterone (PgR), and androgen (AR) receptors were measured in two simultaneous or subsequent specimens taken each from 259 patients with breast cancer. We studied in 182 patients results from receptor assays, either from one tumor or from the primary tumor, and a lymph node metastasis, and in 77 sequential biopsies with or without intervening therapy. All assays were performed in a single laboratory, considering 10 fmol/mg cytosol protein bound ligand as receptor positive. The concordance rate in simultaneous ER assays was 85%; however, we found a considerable high discordance rate for PgR in primary tumor and lymph node metastasis (25%). The overall discordance rate in sequential biopsies for ER was 38% and for PgR 25%. This discordance rate was primarily dependent on the receptor quality of the first assay (ER+: 50%, ER-: 24%, PgR+: 68%, PgR-: 9%). Considering only the ER+ and PgR+ cases, we found the greatest discordance rate in the patients having endocrine treatment following the first biopsy (55% and 84%, respectively). We conclude that the receptor status of one tumor biopsy is highly representative for other tumor or lymph node biopsies. Because of the high discordance rate of primarily receptor + cases in subsequent recurrences, the receptor quality of these lesions should be analyzed whenever possible.
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A CCORDING TO OUR CURRENT KNOWLEDGE, hormonal control of a target cell is receptor-dependent. 1 We wanted to address the following topics: (1) receptor variation within one tumor; (2) relation between concurrent receptor levels in the primary tumor and lymph node metastases; and (3) effect of intervening therapeutic modalities on receptor levels in subsequent biopsies.
Material and Methods Patients
Out of 2,000 receptor determinations performed in our laboratory, tumor samples of 259 patients from one institution from 1977 to 1983 were evaluated for this study. All tissue specimens were histologically proved to be carcinoma of the breast.
Simultaneous Determinations
In 71 patients two tumor samples were assayed (17 of these patients were premenopausal). In 111 patients steroid receptor levels were determined in the primary tumor and one axillary metastasis (30 of these patients were premenopausal). sured by incubating with 200-fold excess of nonradioactive ligand. The incubation mixtures were allowed to reach equilibrium at 4 C for 18 hours and the reaction was terminated by adding dextran-coated charcoal. The number of binding sites was expressed as fmol bound ligand/mg cytosol protein, the dissociation constant was calculated from Scatchard plots'2 using a computer assisted model.'3 A level of at least 10 fmol/mg cytosol protein was considered as receptor positive (+). 
Results
Simultaneous Tumor Samples Table 1 shows the results of steroid receptor determinations from two different samples within the same tumor. We found in 34% both samples ER+, in 51% ER-, resulting in a concordance rate of 85%. Comparable results were obtained when PgR was determined. The percentage of both tumor samples containing no PgR was 10% higher, but the discordance rate of 14% was similar. In 24 cases assayed for AR, the discordance rate was 25%. Looking at the absolute receptor levels, we found that in concordant cases the ER and PgR levels were higher than in discordant specimens ( Table  2 ). The median value for ER in concordant cases was 98 fmol/mg cytosol protein compared to discordant specimens with 37. The levels for PgR were 127 and 32.
Simultaneous Receptor Determinations in Primary and Lymph Node Metastasis
In 111 patients with primary breast cancer and histologically verified axillary metastasis, steroid receptor determinations were performed in samples of the primary and the lymph node metastasis (Table 3) . Fifty-seven primary tumors (51%) and 56 (50%) node metastases were classified as ER+. In 44% we found ER levels higher than 10 fmol/mg cytosol in tumor and metastasis and in 42% both samples were ER-, resulting in an overall concordance between tumor and lymph node metastasis of 86%. In 15 cases (14%) discordant ER levels were obtained. We found in eight cases an ER+ primary and ER-metastasis; however, in seven patients we found an ER+ lymph node in presence of an ERprimary tumor.
PgR+ tumors were seen in 29%, PgR+ nodes in 20%. The concordance rate between primary tumor and axillary node metastases in PgR was 76% (13% were PgR+ and 63% PgR-) in both assays. Interestingly, out of 32 cases with PgR+ tumors, only 14 (44%) showed PgR+ lymph node metastases. However, in eight patients with PgR-primaries we found a PgR+ lymph node metastasis. The concordance rate in AR was 78%. With respect to six discordant cases, five showed AR+ primaries and AR-lymph nodes; however, one showed an AR+ node in presence of an AR-primary tumor.
Sequential Steroid Receptor Assays
In 77 cases, ER levels were measured at different time points either in the primary tumor and later recurrence or in two sequential recurrences. The overall discordance rate between the two biopsies was 38% (Table 4 ). In 40 cases the first biopsy was ER+; however, in 20 patients (50%) the second biopsy was ER-, 37 cases were primarily ER-, and nine (24%) of them showed an ER+ recurrent tumor. Eleven of these 77 patients not treated between the two biopsies developed a discordance rate of 45%, showing more often a change from ERto ER+. Out of 28 patients receiving hormonal treatment, the discordance rate was 43%; out of 12 discordant cases, ten showed a change from ER+ to ER-. Receiving chemotherapy, 12 (32%) of 38 patients showed discordant ER values, eight a change from ER+ to ER-, four from ER-to ER+. The difference between first and second biopsy was statistically significant for that group of patients receiving intervening endocrine treatment compared with the two other groups (Fig. 1) .
Sequential PgR determinations were performed in 71 patients ( (Fig. 2) . It has been appreciated that ER and especially PgR levels in primary breast carcinomas have a major prognostic implication.4'5 Aside from the lymph node status, they are the second most important prognostic parameter. It has been suggested that during the history of breast cancer a dedifferentiation occurs. Therefore one might hypothesize that a frequent change from ER+ to ERand PgR+ to PgR-in subsequent metastases without intervening therapy occurs. However, our own data and results from other investigators'8 9'22-26 do not support this hypothesis. As shown on Table 6 Since the determination of PgR seems to be more important as a prognostic tool and as a predictor for response to endocrine treatment than ER, the "natural" behavior of PgR in sequential biopsies seems to be very important to elucidate in further studies. Furthermore, effects of intervening therapy modalities might be better understood in the view of these findings. We found, as did others (Table 7) , a significant decrease of ER in the subsequent biopsy of patients subjected to endocrine treatment. Out of 18 patients primarily ER+, ten turned in the recurrent tumor to ER-. Taking into account the absolute ER levels, they decreased to a higher extent in this group of patients as did these without intervening therapy or with chemotherapy. However, in four patients primarily ER-the second biopsy revealed ER+ results. There are some arguments discussed in the literature that ER from biopsies of patients treated with antiestrogens might be underestimated due to bound antiestrogens to ER. We would explain this loss of ER (Table 7) . For PgR the discordance rate is only 18%. This is mainly due to the high number of primarily PgR-tumors. Out of 25 PgR-primaries, only two turned to PgR+. It has been suggested that ER-cells are preferentially killed by chemotherapy, a fact that might lead to an increase of ER+ specimens after chemotherapy. Lippman and colleagues29 found a significantly higher response rate in patients with metastatic breast cancer in ER-tumors compared to ER+ tumors. Our data do not support these results.
Conclusion
One has to be cautious to draw final conclusions from these results and from data currently available in the literature. First of all, the number of patients is small, especially in patients with sequential biopsies without intervening therapies and our study, as well as others, is retrospective. Furthermore, usually the first of sequential receptor determinations was performed in the primary tumor, which can add to the variability not due to intervening therapy. The reported studies used different therapeutic regimens that might not necessarily result in similar receptor changes. Furthermore, some changes between two different receptor determinations may be due to assay variations. Keeping these points in mind, we have drawn the following conclusions: 
